BiotechTube
Delve Bio

Delve Bio

San Francisco, United States· Est.
delve.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $105M

Overview

Delve Bio is a commercial-stage diagnostics company commercializing a powerful mNGS platform for the agnostic detection of pathogens in infectious diseases, starting with CNS infections. Its Delve Detect test demonstrates a 22% greater diagnostic yield than conventional methods, with results in 48 hours, backed by real-world evidence from over 4,800 patient samples. The company leverages a proprietary bioinformatics platform (Delve Decide) and a strategic partnership with Broad Clinical Labs for sequencing, positioning itself to address critical gaps in the diagnosis of routine and rare infections.

Infectious Diseases

Technology Platform

Proprietary metagenomic next-generation sequencing (mNGS) platform named 'Delve Decide,' which includes specialized sample processing, a curated database of >68,000 pathogens, an automated bioinformatics pipeline, and expert clinical interpretation for comprehensive pathogen detection.

Funding History

2
Total raised:$105M
Series A$70M
Seed$35M

Opportunities

The significant unmet need for rapid, comprehensive pathogen identification in complex infections, especially in immunocompromised patients or cases of diagnostic uncertainty, presents a large and growing market.
The platform's extensibility allows for expansion into other sample types (blood, respiratory) and disease syndromes (sepsis, pneumonia), offering multiple avenues for growth.

Risk Factors

Key risks include securing consistent and adequate reimbursement from payers for a high-cost test, driving adoption in a market accustomed to traditional diagnostic pathways, and competing with both large diagnostic companies and other mNGS specialists.
Operational risks involve maintaining bioinformatic accuracy and meeting rapid turnaround time promises.

Competitive Landscape

Delve Bio competes with traditional culture and PCR-based tests, syndromic multiplex panels from large diagnostics firms (e.g., BioFire FilmArray), and other mNGS companies like Karius (plasma-based test) and IDbyDNA. Its differentiation lies in its exclusive UCSF lineage, focused CNS test, partnership with Broad Clinical Labs, and integrated clinical interpretation service.

More companies in Diagnostics & Precision Medicine →More companies in United States →